Table 1.
Demographic and clinical characteristics of analyzed subgroups
| ABM (n=41) | Sham (n=21) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Pre-treatment* | Post-treatment | Pre-post statistics | Pre-post effect size [95% CI] | Pre-treatment* | Post-treatment | Pre-post statistics | Pre-post effect size [95% CI] | |
| Caucasian, n (%) | 25 (61%) | – | – | – | 16 (76%) | – | – | – |
| Female, n (%) | 32 (78%) | – | – | – | 16 (76%) | – | – | – |
| Age | 30.85 (9.54) | – | – | – | 29.86 (11.84) | – | – | – |
| Anxiety diagnoses met, n (%): | – | – | – | – | – | – | ||
| GAD | 36 (88%) | 16 (76%) | ||||||
| SAD | 12 (29%) | 9 (43%) | ||||||
| Panic/agoraphobia | 4 (10%) | 3 (14%) | ||||||
| PTSD | 5 (12%) | 1 (5%) | ||||||
| Specific Phobia | 4 (10%) | 2 (10%) | ||||||
| OCD | 4 (10%) | 0 (0%) | ||||||
| Anxiety NOS | 3 (7%) | 3 (14%) | ||||||
| Comorbid depressive disorder | 14 (34%) | 6 (29%) | ||||||
| Number of anxiety diagnoses | 1.68 (1.01) | 1.12 (1.05) | t40=3.501, p=.001 | d=.54 [.22, .87] | 1.57 (0.93) | 1.33 (1.15) | t20=1.227, p=.234 | d=.22 [−.14, .58] |
| Remission of primary anxiety diagnosis, n (%) | – | 15 (37%) | – | – | – | 3 (14%) | – | – |
| Remission of all anxiety diagnoses, n (%) | – | 10 (24%) | – | – | – | 1 (5%) | – | – |
| CAPS-Vigilance | 4.54 (2.03) | 3.90 (1.97) | t40=2.500, p=.017 | d=.32 [.07, .58] | 5.24 (2.23) | 4.19 (2.16) | t20=2.796, p=.011 | d=.48 [.13, .83] |
| MASQ: Anxious Arousal | 32.20 (10.66) | 27.41 (8.59) | t40=5.136, p<.001 | d=.47 [.28, .66] | 34.05 (10.72) | 30.29 (13.92) | t20=1.642, p=.116 | d=.29 [−.06, .65] |
| MASQ: General Distress (anxiety) | 25.49 (6.98) | 22.17 (6.42) | t40=3.893, p<.001 | d=.49 [.23, .76] | 27.76 (7.28) | 25.38 (9.36) | t20=1.330, p=.199 | d=.28 [−.14, .70] |
| High Response Quartile (n=10): Post-treatment | Low Response Quartile (n=10): Post-treatment | Φ Between-group difference: High vs. Low Quartile | Sham (n=21): Post-treatment | Φ Between-group difference at post-treatment: High ABM quartile vs. all sham | |
|---|---|---|---|---|---|
| Number of anxiety diagnoses | 0.60 (0.84) | 1.60 (1.51) | t18=−1.833, p=.083 | 1.33 (1.15) | t29=1.787, p=.084 |
| Remission of all anxiety diagnoses, n (%) | 4 (40%) | 2 (20%) | X2=0.952, p=.329 | 1 (5%) | X2=6.218, p=.013 |
| CAPS-Vigilance | 1.70 (1.64) | 5.80 (1.23) | t18=−6.335, p<.001 | 4.19 (2.16) | t29=3.222, p=.003 |
| MASQ: Anxious Arousal | 23.30 (6.41) | 32.10 (11.28) | t18=−2.145, p=.046 | 30.29 (13.92) | t29=1.503, p=.144 |
| MASQ: General Distress (anxiety) | 19.40 (5.78) | 26.30 (8.38) | t18=−2.144, p=.046 | 25.38 (9.36) | t29=1.850, p=.075 |
Note: Data presented as mean (SD) unless otherwise noted. CAPS-Vigilance=Clinician-Administered PTSD Scale, hypervigilance item; MASQ=Mood and Anxiety Symptoms Questionnaire; GAD=Generalized Anxiety Disorder; SAD=Social Anxiety Disorder; PTSD=Posttraumatic Stress Disorder; OCD=Obsessive-Compulsive Disorder; NOS=Not Otherwise Specified.
No baseline differences were observed for ABM vs. sham groups on any demographic or clinical variable according to t-tests (continuous variables) or X2 (categorical variables) (p’s>.24).
Exploratory post hoc comparisons of High Response Quartile to other groups are presented to provide descriptive comparisons of whether groups defined on the basis of CAPS residual scores exhibited more generalized clinical differences at post-treatment.